JPS62126130A - Medicinal composition for animals - Google Patents
Medicinal composition for animalsInfo
- Publication number
- JPS62126130A JPS62126130A JP27383586A JP27383586A JPS62126130A JP S62126130 A JPS62126130 A JP S62126130A JP 27383586 A JP27383586 A JP 27383586A JP 27383586 A JP27383586 A JP 27383586A JP S62126130 A JPS62126130 A JP S62126130A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- citric acid
- composition
- veterinary pharmaceutical
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は家畜の障害を治療するのに有用な動物用医薬組
成物に関しそして特に家畜の下痢（例えば白痢）を治療
するのに有用な組成物に関しさらに再水和作用による下
痢の治療におけるこのような組成物の用途に関する。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to veterinary pharmaceutical compositions useful for treating disorders in livestock, and in particular compositions useful for treating diarrhea (e.g., white diarrhea) in livestock. It further relates to the use of such compositions in the treatment of diarrhea by rehydration.
若い家畜例えば仔牛及び仔豚を襲う普通のしかも非常に
弱らせる疾患は下痢である。下痢は激しい脱水を生じさ
せ、それは次に動物の体重を極めて減少させそしてひど
い場合には死に至らしめる。A common and very debilitating disease that affects young livestock, such as calves and piglets, is diarrhea. Diarrhea causes severe dehydration, which in turn causes severe weight loss in the animal and in severe cases leads to death.
しばしば下痢の症状は細菌性の１種以上の毒素により引
き起されそのため下痢を治療する一つの方法は抗菌剤の
投与にあると考えられている。かなりの成功が抗菌剤例
えばアンピシリン又はアモキシリンの使用により達成さ
れるが別の療法が要求される場合もある。Diarrheal symptoms are often caused by one or more bacterial toxins and therefore one method of treating diarrhea is thought to be the administration of antimicrobial agents. Although considerable success has been achieved with the use of antibacterial agents such as ampicillin or amoxicillin, other therapies may be required.
英国特許第１．５８１．８２６号明細書は処方の容易さ
、嗜好性及び有用な安定性と有効性を組合わせた家畜の
下痢の治療用の組成物を開示している。GB 1.581.826 discloses compositions for the treatment of diarrhea in livestock that combine ease of formulation, palatability and advantageous stability and efficacy.
この組成物は活性的に吸収される単糖、活性的に吸収さ
れる天然のアミノ酸及びくえん酸又はその塩よりなる。The composition consists of an actively absorbed monosaccharide, an actively absorbed natural amino acid and citric acid or its salt.
新しい組成物が見い出されそれは英国特許第１、５８１
．８２６号明細書に開示されたものの利点をすべて有し
その上治療された家畜例えば仔ウシ、仔ブタ、ウマ、イ
ヌ及びネコの腸管から水を吸収する非常に改良された能
力を示す。さらに本発明の組成物は用いられてこれら動
物のアシドージスネルギーをもたらすのに用いられよう
。A new composition was discovered and it was published in British Patent No. 1,581.
．． It has all the advantages of that disclosed in '826 and yet exhibits a greatly improved ability to absorb water from the intestinal tract of treated livestock such as calves, piglets, horses, dogs and cats. Additionally, the compositions of the present invention may be used to effect acidosis in these animals.
従って本発明は６０〜８５％の活性的に吸収される単糖
類、３．５俤から７５チより少い活性的に吸収される天
然のアミン？、０．５〜１０％の剤（くえん酸及び／又
はその１種以上の塩である）よりなる動物用医薬組成物
を提供する。Therefore, the present invention contains 60-85% actively absorbed monosaccharides, 3.5 to 75% less actively absorbed natural amines? , 0.5 to 10% of an agent (citric acid and/or one or more salts thereof).
本明細書で用いられるすべてのチは重量／全重量の基準
により計算される。All parts used herein are calculated on a weight/total weight basis.
本発明は又上述の成分を必要な割合で混合することより
なり動物用医薬組成物を製造する方法を提供する。The present invention also provides a method for producing a veterinary pharmaceutical composition comprising mixing the above-mentioned components in the required proportions.
この点に関し標準の教科書例えばガイトン（Ｇｕｙｔｏ
ｎ ）の「メデイシナル・フイジオロジー（Ｍｅｄｉｃ
ｉｎａｌ Ｐｈｙｓｉｏｌｏｇｙ’ ）Ｊ （ダブリュ
ー争ビーサンダーズ・アンド・カンパニー（Ｗ、Ｂ、５
ａｖｎｄｅｒｓ吸収されるか否かは又例えばティ・エッ
チ・ウィルソン（Ｔ、）Ｔ、ＷｉＪｓｏｎ ）の［イソ
テスチナル・アブソープション（Ｉｎｔｅｓｔｉｎａｌ
Ａｂｓｏｒｐｔｉｏｎ ） Ｊ Ｃサンダーズ、フィ
ラデルフィア、１９６２年］に記載されているように実
験により容易に決められよに少くとも６Ｉ？ｌｉＩの炭
素原子；（ｂ）Ｄ−ピラノース壌構債；そして（ｃ）
、Ｗ素２におけるその１１のヒドロＣ２−７アシル］ヒ
及びＣ１−４アルキル化誘導体例えばア′セチル、メチ
ル、エチル及びｎ−及びイソ−プロピル誘導体を含む。There are standard textbooks on this point, such as Guyton's
n)'s ``Medicinal Physiology''
inal Physiology') J (W, B, 5
Whether avnders are absorbed or not can also be determined by, for example, T.H. Wilson (T., T., WiJson)
At least 6I? carbon atom of liI; (b) D-pyranose structure; and (c)
, including its 11 hydroC2-7acyl]h and C1-4 alkylated derivatives in W2, such as a'cetyl, methyl, ethyl and n- and iso-propyl derivatives.
特定の例はα−メチルグルコシド
のグルコースであっても又は水加さｎた形例えばグルコ
ース１水イピ物でも用いられる。A particular example is the α-methyl glucoside glucose or even the hydrated form such as glucose monohydrate.
活性的に吸収される天然のアミノ酸は中性アミノ酸例え
ばクリシン及びアラニン炙塩塞性アミノ酸例えばアルギ
ニンを含む。好ましくはアミノ酸はグリシンである。Natural amino acids that are actively absorbed include neutral amino acids such as chrysine and alanine and occlusive amino acids such as arginine. Preferably the amino acid is glycine.
くえん酸の塩の適当な例はナトリウム又はカリウム塩例
えばくえん酸のー、二又は三ナトリウム又は−、二又は
三カリウム塩及び塩酸例えばくえん酸水素二ナトリウム
及びくえん酸水素二カリウムを含む。くえん酸及びその
塩は無水でも又は本稿されていてもよい。Suitable examples of salts of citric acid include sodium or potassium salts such as the -, di- or trisodium or -, di- or tripotassium salts of citric acid and hydrochloric acids such as disodium hydrogen citrate and dipotassium hydrogen citrate. Citric acid and its salts may be anhydrous or oxidized.
本発明の動物用医薬組成物は通常５〜２５％の電解質を
含むだろう。適当な４解質はイオン例えばナトリウム、
カリウム、カルシウム、マグネジ他の好ましい電解質は
りん酸三カリウム、塩化９んなどを含む。The veterinary pharmaceutical compositions of the invention will normally contain 5-25% electrolytes. Suitable 4 solutes include ions such as sodium,
Preferred electrolytes such as potassium, calcium, and magnesium include tripotassium phosphate, potassium chloride, and the like.
有利には組成物はバッファー剤例えばりん酸二水素カリ
ウム、りん酸水素二カリウムなどケ含む。Advantageously, the composition includes a buffering agent such as potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and the like.
特に適当なバッファー剤はりん酸二水素カリウムであっ
て通常、組成物の０．５〜５チ、普通、組成物の１〜３
チに相当する。適当には組成物は下痢をしている動物へ
の投与用の水溶液のｐＨが５． ０〜７、０好ましくは
５．５〜６．５の範囲内にあるように処方される。A particularly suitable buffering agent is potassium dihydrogen phosphate, usually from 0.5 to 5 parts of the composition, usually from 1 to 3 parts of the composition.
Corresponds to Suitably the composition is such that the pH of the aqueous solution for administration to animals suffering from diarrhea is 5. It is prescribed to be within the range of 0 to 7, preferably 5.5 to 6.5.
本発明の組成物に含まれる他の好ましい電解質は塩化す
） １３ウムでありそれは通常組成物の４〜定される。Another preferred electrolyte included in the compositions of the present invention is 13 um of chloride, which is usually determined from 4 to 10 um of the composition.
ざらに適当にはそれは組成物の７０〜に組成物中のアミ
ノ酸が組成物の３．５チから７．５チより少い■を占め
るが、さらに適当にはそれは組成物の３．５〜６，０チ
例えば組成物の３．５〜５％を占めるだろう。More suitably it is such that the amino acids in the composition account for less than 3.5 to 7.5 parts of the composition, but more suitably it is less than 3.5 parts to 7.5 parts of the composition. For example, 6.0% would represent 3.5-5% of the composition.
前述から本発明の特に適当な動物用医薬組成物が７０〜
８５％のグルコース又はガラクトース、３、５〜６チの
グリシン、アラニン又はアルギニン、０、５〜１０幅の
くえん酸及び／又は１種以上のその塩、１〜３チのりん
酸二水素カリウム及び５〜１０％の塩化ナトリウムより
なることが分るだろう。From the foregoing, particularly suitable veterinary pharmaceutical compositions of the present invention include
85% glucose or galactose, 3,5-6% glycine, alanine or arginine, 0,5-10% citric acid and/or one or more salts thereof, 1-3% potassium dihydrogen phosphate and It will be seen that it consists of 5-10% sodium chloride.
特に適当な一つのタイプの組成物はくえん酸及び１種以
上のその塩よりなる。One type of composition that is particularly suitable consists of citric acid and one or more salts thereof.
好ましくはこの組成物はともに組成物の０．５〜１０％
しばしば組成物の５〜１０％を占めるくえん酸、くえん
酸ナトリウム及びくえん酸カリウムの混合物を含む。有
利にはこの組成物は０．５〜５チのくえん酸及び０．１
〜９．５チのくえん酸の三ナトリウム及び三カリウムの
混合物を含むだろう。Preferably the compositions together make up 0.5-10% of the composition.
It contains a mixture of citric acid, sodium citrate and potassium citrate, often accounting for 5-10% of the composition. Advantageously, the composition contains 0.5-5 citric acid and 0.1
It will contain a mixture of trisodium and tripotassium citric acid of ~9.5%.
好都合にはくえん酸、くえん酸す） ＩＪウム及びくえ
ん酸カリウムは水和された形である。Conveniently citric acid, potassium citrate) and potassium citrate are in hydrated form.
本発明の一つの好ましい組成物は７０〜８５％ノクルコ
ース、３．５〜６％のクリシン、０．５〜２チのくえん
酸、５〜９．５％のくえん酸の三ナトリウム及び三カリ
ウムの混合物、５〜１０％の塩化ナトリウム、及び１〜
３チのりん酸二水素カリウムよりなる。One preferred composition of the invention is 70-85% nocurcose, 3.5-6% chrysin, 0.5-2 citric acid, 5-9.5% trisodium citric acid and tripotassium. a mixture of 5-10% sodium chloride, and 1-
Consists of 30% potassium dihydrogen phosphate.
特に好ましい組成物は少くとも７５チのグルコースより
なる。A particularly preferred composition consists of at least 75 grams of glucose.
特に適当な第二のタイプの動物用医薬組成物はくえん酸
の１種以上の塩よりなるが塩の形ではないくえん酸を含
まない。A particularly suitable second type of veterinary pharmaceutical composition comprises one or more salts of citric acid, but does not contain citric acid that is not in salt form.
従って本発明の他の好ましい組成物は７０〜８５チのグ
ルコース、３．５〜６１％のグリシン、０、５〜１０チ
の塩化ナトリウムよりなる。この組成物はしばしば１〜
３％のりん酸二水素カリウムを含む。有利にはこの組成
物は組成物の０．５〜１０％を占めるくえん酸水素二ナ
トリウム、くえん酸三ナトリウム及びくえん酸三カリウ
ムの混合物を含む。好都合にはこれらのくえん酸塩は水
和された形である。Accordingly, another preferred composition of the invention consists of 70-85% glucose, 3.5-61% glycine, and 0.5-10% sodium chloride. This composition is often 1-
Contains 3% potassium dihydrogen phosphate. Advantageously, the composition comprises a mixture of disodium hydrogen citrate, trisodium citrate and tripotassium citrate, representing from 0.5 to 10% of the composition. Conveniently these citrates are in hydrated form.
このタイプの特に好ましい組成物は８０〜８３チのグル
コース１水化物、３．５〜４％のグリシン、５〜７％の
塩化ナトリウム、１．５〜２％のりん酸二水素カリウム
、０．５〜１％のくえん酸三ナトリウム２水化物、２．
０〜２．５％のくえん酸水素二ナトリウムセスキ水化物
及び４．０〜４．５％のくえん酸三カリウム１水化物よ
りなる。A particularly preferred composition of this type is 80 to 83% glucose monohydrate, 3.5 to 4% glycine, 5 to 7% sodium chloride, 1.5 to 2% potassium dihydrogen phosphate, 0.8% to 80% glucose monohydrate, 3.5 to 4% glycine, 5 to 7% sodium chloride, 1.5 to 2% potassium dihydrogen phosphate. 5-1% trisodium citrate dihydrate, 2.
It consists of 0-2.5% disodium hydrogen citrate sesquihydrate and 4.0-4.5% tripotassium citrate monohydrate.
もし所望ならば本発明の組成物は他の物質例えばビタミ
ン、ミネラル、バッファー剤、添加物などを従来のやり
方で含む。If desired, the compositions of the invention may contain other substances such as vitamins, minerals, buffers, additives, etc. in a conventional manner.
一般に本発明の組成物は乾燥粉末例えば水に容易に溶解
するものの形であろう。しかし他の様相において本発明
の組成物は前述の相対的な割合で前述の溶質をその中に
溶解して含む水溶液よりなるだろう。Generally, the compositions of the invention will be in the form of a dry powder, such as one that is readily soluble in water. However, in other embodiments, the composition of the invention will consist of an aqueous solution containing dissolved therein the aforementioned solutes in the aforementioned relative proportions.
本発明の粉末は従来のやり方で個々の成分をともに混合
することによソ１製造されよう。一度混合分を分離する
のはしばしば有利である。これは別々のパック又は二組
のパック又は他の二重の容器一つのパック又は二重のパ
ックの半分に充填されよう。この形のとき本発明の組成
物は特に安定であることが分った。The powders of the present invention may be manufactured by mixing the individual components together in a conventional manner. It is often advantageous to separate the mixture once. This may be filled in separate packs or double packs or other double containers in half of a single pack or double pack. In this form, the compositions of the invention have been found to be particularly stable.
７．５％より少い活性的に吸収される天然のアミノ酸及
び０．５〜１０俤のくえん酸及び／又は１種以上のその
塩である剤を保有する別の容器よりなる一対のパックを
提供する。A pair of packs consisting of separate containers containing less than 7.5% of actively absorbed natural amino acids and 0.5 to 10 doses of citric acid and/or one or more salts thereof. provide.
俤より少い活性的に吸収される天然のアミノ酸及び０．
５〜１０チのくえん酸及び／又は１種以上のその塩であ
る剤を他の容器に充填することよりなる一対のパックを
１造する方法を提供する。Natural amino acids that are actively absorbed and less than 0.
To provide a method for making a pair of packs by filling another container with 5 to 10 citric acid and/or one or more salts thereof.
各成分のパーセントは一対のパックに含まれる本発明の
組成物の全重量に対するその成分の相対的割合（１就）
を示す。The percentage of each ingredient refers to the relative proportion of that ingredient to the total weight of the composition of the invention contained in a pair of packs.
shows.
本発明の組成物はもし心安ならば胃管を用いて経口経路
により水溶液の形で下痢をしている動物へ通常投与され
よう。この溶液は例えば本組成物’ｔ２０〜４５ ｙ／
ｇａａニｈｚ ５〜４０９／１１含むだろう。一般に仔
ウシはこの溶液の４〜６ｅ（１日）を投与されるが仔ブ
タは通常１日当９４分の１ｇ〜１１を投与されるだろう
。溶液は自由に投与されるか又は１日当９２〜４回又は
それ以上の等しい投与量で又は任意の他の同様な従来の
療法により投与さ゛れよう。The compositions of the present invention will normally be administered to animals with diarrhea in the form of an aqueous solution by the oral route using a gastric tube if safe. This solution is, for example, the present composition 't20-45 y/
It will include gaa Nihz 5-409/11. Generally calves will receive 4 to 6 e (per day) of this solution, while piglets will usually receive 1/94 g to 11 g per day. The solution may be administered ad libitum or in equal doses of 92 to 4 or more times per day or by any other similar conventional therapy.
成る条件下では本組成物の適当に製造されそして滅菌さ
れた水溶液は静脈内に投与されよう。Under these conditions, a suitably prepared and sterile aqueous solution of the composition may be administered intravenously.
本発明の他の様相は家畜の下痢を治療する方法を提供し
その方法は水性媒体に溶解した本発明の組成物を下痢に
かかった動物に投与することよりなる。Another aspect of the invention provides a method of treating diarrhea in livestock, the method comprising administering to an animal suffering from diarrhea a composition of the invention dissolved in an aqueous medium.
下痢のひどい動物の治療に抗菌剤を本発明の組成物とと
もに投与されうることは理解されよう。It will be appreciated that antimicrobial agents may be administered with the compositions of the present invention to treat animals with severe diarrhea.
この用途の適当な抗菌剤の例はアンピシリン、アモキシ
シリン及びテトラサイクリンを含む。Examples of suitable antimicrobial agents for this use include ampicillin, amoxicillin and tetracycline.
水性媒体に溶解されたとき本発明の組ｔｒｉ物について
見い出される有効な吸収性は動物による液体の吸収が間
鴫であるときは何時でも有利に用いられうろことは当業
者は理解されよう。例えば組成物は動物例えばイヌ及び
ネコにおける手術後の状態に見い出される一般的な脱水
を治療するのに用適当な容量の水に溶解した（例えば６
０〜１００９／２００ｄ ）本発明の組成物は又ヒツジ
又はウシのケトー多スにともなう低血糖症の治療に用い
られよう。Those skilled in the art will appreciate that the effective absorbency found for the compositions of the present invention when dissolved in aqueous media can be used to advantage whenever absorption of liquid by an animal is slow. For example, the composition may be dissolved in a volume of water suitable for treating the common dehydration found in post-surgical conditions in animals such as dogs and cats (e.g.
0-1009/200d) The compositions of the invention may also be used in the treatment of hypoglycemia associated with hyperketosis in sheep or cattle.
従って本発明の他の様相はヒツジ又はウシのケト−ジス
にともなう低血糖症を治療する方法を提供しその方法は
水性媒体に溶解した本発明の組成物をそれにかかつ念勅
物に投与することよりなる。Accordingly, another aspect of the invention provides a method of treating hypoglycemia associated with ketosis in sheep or cattle, the method comprising administering thereto a composition of the invention dissolved in an aqueous medium, and It's more than that.
下記の実施例は本発明を説明する。 The following examples illustrate the invention.
実施例１
合計で７７．４５９の下記の組成物を乾燥粉末の形の下
記の成分をともに混合することにより製造した０
９ 全体のチ
グルコース１水化物 ６２．７
８０．９６グリシン ３．０
３．８７塩化ナトリウム
４．６ ５．９４りん酸二水素カリウム
１．４ １．８１くえん酸１
水化物 ０．５ ０．６５
くえん酸三ナトリウム２水化物 ２．０
２．５ Ｂくえん酸三カリウム１水化物 ３．
２５ ４．１９全組成物を次に２ｅの水に溶解
したＯ
実施例２
貯蔵のために実施例１による組成物を同一のやり方で装
機したがグルコース１水化物（６２，７９）を一つのパ
ックに充填しそして他の成分（１４，７５９）を第二の
パックに充填した。Example 1 A total of 77.459 0 9 total tiglucose monohydrate prepared by mixing together the following components in dry powder form: 62.7
80.96 Glycine 3.0
3.87 Sodium chloride
4.6 5.94 Potassium dihydrogen phosphate 1.4 1.81 Citric acid 1
Hydrate 0.5 0.65
Trisodium citrate dihydrate 2.0
2.5 B Tripotassium citrate monohydrate 3.
25 4.19 The entire composition was then dissolved in 2e water. Example 2 The composition according to Example 1 was packaged in the same way for storage, but glucose monohydrate (62,79) was One pack was filled and the other ingredients (14,759) were filled into a second pack.
実施例３
合計で７７．４１９の下記の組成物を乾燥粉末の形の下
記の成分をもとに混合することにより製造した０
９ 全体のチ
グルコース１水化物 ６２．７
８１．００グリシン
３．０ ３．８７塩化ナトリウム
４．６ ５．９４りん酸二水素カ
リウム １．４ １．８１
くえん酸三ナトリウム・２ＨｚＯＯ，６６０，８５くえ
ん酸水素ナトリウム・１寺Ｈ，０１，８０２，３３くえ
ん酸三カリウム・ＩＨｘ Ｏ３，２５４，２０水組成物
を使用のため２ｇの水に溶解した。Example 3 0 9 total tiglucose monohydrate prepared by mixing the following composition in dry powder form with a total of 77.419 62.7
81.00 Glycine
3.0 3.87 Sodium chloride
4.6 5.94 Potassium dihydrogen phosphate 1.4 1.81
Trisodium citrate, 2 Hz OO, 660,85 Sodium hydrogen citrate, 1 Temple H, 01,802,33 Tripotassium citrate, IHx O3,254,20 Water The composition was dissolved in 2 g of water for use.
貯蔵の九めにグルコース１水化物（６２，７，９）を一
つのパックに充填しそして他の成分（１４，７１９）′
！−第二のパックに充填した。At the ninth stage of storage, glucose monohydrate (62,7,9) was filled into one pack and other ingredients (14,719)'
! - Filled the second pack.
生物学上のデータ
急性の吸収の研究を実施例１の組成物についてそれを２
ｇの水に溶解した後に行った。Biological Data Acute Absorption Studies for the Composition of Example 1 and 2
g after dissolving in water.
用いられた方法は麻酔をかけたオスの仔ウシに２０チ、
５０％、７０チそして９５％の５個所の小腸に沿った点
を確認した。それぞれの点において一連の短い長さの腸
を結さくにより単離しな。The method used was to inject 20 chi into an anesthetized male calf.
Five points along the small intestine were identified: 50%, 70%, and 95%. Isolate a series of short lengths of intestine at each point by ligation.
をフェノールレッドの濃度の変化を測定することにより
求めた。was determined by measuring the change in the concentration of phenol red.
得られた結果を下記の表に示した。The results obtained are shown in the table below.
表
５ ０．２０ ±０．０３
２０ ０．１９ ±０．０
５５０ ０．２７ ±０．０３
代理人 ０．２２ ±０
．０５９５ ０．１３ ±
０．０３代理人 弁理士 秋 沢 政 光
他１名Table 5 0.20 ±0.03
20 0.19 ±0.0
550 0.27 ±0.03
Agent 0.22 ±0
．． 0595 0.13 ±
0.03 Agent Patent attorney Masamitsu Akizawa and 1 other person
Claims (17)
５％から７．５％より少い活性的に吸収される天然のア
ミノ酸、及び０．５〜１０％のくえん酸及び／又は１種
以上のその塩である物質よりなる動物用医薬組成物。(1) 60-85% actively absorbed monosaccharides; 3.
A veterinary pharmaceutical composition comprising from 5% to less than 7.5% of a substance which is actively absorbed natural amino acids and from 0.5 to 10% of citric acid and/or one or more salts thereof.
（１）項記載の組成物。(2) The composition according to claim (1), consisting of 70 to 85% monosaccharides.
範囲第（１）又は（２）項記載の組成物。(3) The composition according to claim (1) or (2), comprising 3.5 to 6.0% of amino acids.
請求の範囲第（１）〜（３）項の何れか一つの項記載の
組成物。(4) The composition according to any one of claims (1) to (3), wherein the monosaccharide is glucose or galactose.
ある特許請求の範囲第（１）〜（４）項の何れか一つの
項記載の組成物。(5) The composition according to any one of claims (1) to (4), wherein the amino acid is glycine, alanine, or arginine.
請求の範囲第（１）〜（５）項の何れか一つの項記載の
組成物。(6) The composition according to any one of claims (1) to (5), further comprising 5 to 25% sodium chloride.
液のｐＨが５．０〜７．０の範囲内にあるバッファー剤
よりなる特許請求の範囲第（１）〜（６）項の何れか一
つの項記載の組成物。(7) Any of claims (1) to (6) further comprising a buffer agent whose aqueous solution has a pH within the range of 5.0 to 7.0 for administration to animals suffering from diarrhea. A composition according to item 1.
．５〜６％のグリシン、アラニン又はアルギニン、０．
５〜１０％のくえん酸及び／又は１種以上のその塩、１
〜３％のりん酸二水素カリウム及び５〜１０％の塩化ナ
トリウムよりなる特許請求の範囲第（７）項記載の組成
物。(8) 70-85% glucose or galactose, 3
．． 5-6% glycine, alanine or arginine, 0.
5-10% citric acid and/or one or more salts thereof, 1
A composition according to claim 7, comprising ~3% potassium dihydrogen phosphate and 5-10% sodium chloride.
囲第（１）〜（８）項の何れか一つの項記載の組成物。(9) The composition according to any one of claims (1) to (8), which does not contain citric acid that is not in the form of a salt.
４％のグリシン、５〜７％の塩化ナトリウム、１．５〜
２％のりん酸二水素カリウム、０．５〜１％のくえん酸
三ナトリウム２水化物、２．０〜２．５％のくえん酸水
素二ナトリウムセスキ水化物及び４．０〜４．５％のく
えん酸三カリウム１水化物よりなる特許請求の範囲第（
１）〜（９）項の何れか一つの項記載の組成物。(10) 80-83% glucose monohydrate, 3.5-
4% glycine, 5-7% sodium chloride, 1.5-
2% potassium dihydrogen phosphate, 0.5-1% trisodium citrate dihydrate, 2.0-2.5% disodium hydrogen citrate sesquihydrate and 4.0-4.5% Claim No. 1 consisting of tripotassium citrate monohydrate (
The composition according to any one of items 1) to (9).
）項の何れか一つの項記載の組成物。(11) Claims (1) to (10) which are aqueous solutions
) The composition described in any one of the following items.
〜（１１）項の何れか一つの項記載の組成物。(12) Claim No. (1) further includes an antibacterial agent.
The composition according to any one of items 1 to 11.
有する一つの容器並びに３．５％から７．５％より少い
活性的に吸収される天然のアミノ酸及び０．５〜１０％
のくえん酸及び／又は１種以上のその塩である物質を保
有する他の容器よりなる一対のパック。(13) One container holding 60-85% actively absorbed monosaccharides and 3.5% to less than 7.5% actively absorbed natural amino acids and 0.5-10 %
A pair of packs consisting of another container containing a substance which is citric acid and/or one or more salts thereof.
許請求の範囲第（１）項記載の動物用医薬組成物の用途
。(14) Use of the veterinary pharmaceutical composition according to claim (1) for producing a drug for treating diarrhea in livestock.
治療用の薬剤を製造するための特許請求の範囲第（１）
項記載の動物用医薬組成物の用途。(15) Claim No. 1 for producing a drug for the treatment of hypoglycemia associated with ketosis in sheep or cattle.
Uses of the veterinary pharmaceutical compositions described in Section 1.
る特許請求の範囲第（１）項記載の動物用医薬組成物を
製造する方法。(16) A method for producing a veterinary pharmaceutical composition according to claim (1), which comprises mixing the ingredients together in the required proportions.
に記載された動物用医薬組成物。(17) A veterinary pharmaceutical composition substantially as described herein with respect to any one of the Examples.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8528307 | 1985-11-18 | ||
| GB858528307A GB8528307D0 (en) | 1985-11-18 | 1985-11-18 | Veterinary compositions |
| GB8605689 | 1986-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62126130A true JPS62126130A (en) | 1987-06-08 |
Family
ID=10588354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP27383586A Pending JPS62126130A (en) | 1985-11-18 | 1986-11-17 | Medicinal composition for animals |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS62126130A (en) |
| GB (1) | GB8528307D0 (en) |
| ZA (1) | ZA868691B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006511504A (en) * | 2002-11-11 | 2006-04-06 | ファーマレット エイ／エス | Pharmaceuticals for use as therapeutics |
| JP2012519690A (en) * | 2009-03-04 | 2012-08-30 | メタアクティブ、インコーポレイテッド | Method and material for forming site-activated complex of biomolecule |
| US8809399B1 (en) | 2012-12-23 | 2014-08-19 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms triggered by stress |
| US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
| US9636361B2 (en) | 2007-12-28 | 2017-05-02 | Liveleaf, Inc. | Method of killing a bacteria with a plant-based biocidal solution |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5088212A (en) * | 1973-12-03 | 1975-07-15 | ||
| JPS54101437A (en) * | 1977-12-23 | 1979-08-10 | Beecham Group Ltd | Orally dosing composition and production |
| JPS57120517A (en) * | 1981-01-21 | 1982-07-27 | Nisshin Flour Milling Co Ltd | Composition for preparing oral supplementary solution |
-
1985
- 1985-11-18 GB GB858528307A patent/GB8528307D0/en active Pending
-
1986
- 1986-11-17 JP JP27383586A patent/JPS62126130A/en active Pending
- 1986-11-17 ZA ZA868691A patent/ZA868691B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5088212A (en) * | 1973-12-03 | 1975-07-15 | ||
| JPS54101437A (en) * | 1977-12-23 | 1979-08-10 | Beecham Group Ltd | Orally dosing composition and production |
| JPS57120517A (en) * | 1981-01-21 | 1982-07-27 | Nisshin Flour Milling Co Ltd | Composition for preparing oral supplementary solution |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006511504A (en) * | 2002-11-11 | 2006-04-06 | ファーマレット エイ／エス | Pharmaceuticals for use as therapeutics |
| US10525080B2 (en) | 2007-12-28 | 2020-01-07 | Liveleaf, Inc. | Increasing the half-life of hydrogen peroxide in an ingestible composition |
| US9636361B2 (en) | 2007-12-28 | 2017-05-02 | Liveleaf, Inc. | Method of killing a bacteria with a plant-based biocidal solution |
| JP2012519690A (en) * | 2009-03-04 | 2012-08-30 | メタアクティブ、インコーポレイテッド | Method and material for forming site-activated complex of biomolecule |
| JP2016000743A (en) * | 2009-03-04 | 2016-01-07 | ライブリーフ，インコーポレーテッド | Method and material for site activated complexing of biologic molecules |
| US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
| US8946304B2 (en) | 2012-12-23 | 2015-02-03 | Liveleaf, Inc. | Methods of treating malnutrition |
| US9089596B1 (en) | 2012-12-23 | 2015-07-28 | Liveleaf, Inc. | Methods of treating drug side-effects that include a gastrointestinal spasm |
| US9023895B1 (en) | 2012-12-23 | 2015-05-05 | Liveleaf, Inc. | Methods of treating necrotic enteritis |
| US9603871B2 (en) | 2012-12-23 | 2017-03-28 | Liveleaf, Inc. | Methods of treating gastroesophageal reflux disease |
| US9603883B2 (en) | 2012-12-23 | 2017-03-28 | Liveleaf, Inc. | Methods of inhibiting a bacterial virulence in a subject |
| US8822545B1 (en) | 2012-12-23 | 2014-09-02 | Liveleaf, Inc. | Tannin formulation for treating gastrointestinal spasms triggered by stress |
| US9907818B2 (en) | 2012-12-23 | 2018-03-06 | Liveleaf, Inc. | Methods of treating a treatment-resistant gastrointestinal spasm |
| US10039784B2 (en) | 2012-12-23 | 2018-08-07 | Liveleaf, Inc. | Methods of treating a treatment-resistant gastrointestinal spasm with an oxidized tannin |
| US10493102B2 (en) | 2012-12-23 | 2019-12-03 | Liveleaf, Inc. | Methods of inhibiting the virulence of a pathogen with an oxidized tannin to treat a gastrointestinal spasm |
| US8809399B1 (en) | 2012-12-23 | 2014-08-19 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms triggered by stress |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8528307D0 (en) | 1985-12-24 |
| ZA868691B (en) | 1987-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5008248A (en) | Veterinary compositions for the treatment of scours and dehydration | |
| US3898328A (en) | Dry stable composition for the treatment of scours and dehydration | |
| US4164568A (en) | Oral scour formulations with citrate | |
| US4520014A (en) | Treatment of diarrhoea | |
| JP2784092B2 (en) | How to prevent or treat calcium deficiency in cattle | |
| JPS5810519A (en) | Medicinal composition | |
| US2477080A (en) | Antacid preparation | |
| US4387093A (en) | Arthritis treatment | |
| US3621094A (en) | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts | |
| US4931290A (en) | Milk fever prophylactic treatment and composition | |
| US5631289A (en) | Use of calcium formate in orally administrable compositions | |
| US20020169212A1 (en) | Ketoprofen powder for oral use | |
| JPS62126130A (en) | Medicinal composition for animals | |
| ES2342678T3 (en) | USE OF LANTAN CARBONATES FOR THE REDUCTION OF DIGESTIBILITY OF PHOSPHORUS IN ANIMAL NUTRITION. | |
| US20070265344A1 (en) | Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals | |
| US5560920A (en) | Calcium formulations for prevention of parturient hypocalcemia | |
| RU2437653C1 (en) | Method of treatment and prevention of gastrointestinal diseases in newborn calves | |
| US3928578A (en) | Composition for control of white muscle disease | |
| CN104983686A (en) | Meloxicam soluble powder for livestock and poultry and preparation method thereof | |
| Magdesian | Maintenance fluid therapy in horses | |
| EP0059057A1 (en) | Treatment of diarrhoea | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| JPS63503306A (en) | Veterinary pharmaceutical composition | |
| RU2103997C1 (en) | Medicinal agent for treatment of animal disease of bacterial etiology, method of treatment of animal gastroenteric disease of bacterial etiology and methods of treatment of gynecological disease of bacterial etiology in animals | |
| JPS60260510A (en) | Injection solution for ketonemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 19960409 |